The effect of pregnancy on renal angiomyolipoma; a world of knowledge to gain, specifically in women with TSC

Autor: Marlou W. Kluiving, Evelien F. H. I. Peeters, Titia A. Lely, Niek van Oorschot, Wendela L. de Ranitz-Greven

Publikováno v: BMC Nephrology, Vol 25, Iss 1, Pp 1-9 (2024)

Abstract Background Women are counseled preconceptionally about the potential risks of rAML progression and chance of complications during and due to pregnancy. However, a systematic search investigating the evidence on which this advice is based doe

Externí odkaz: https://doaj.org/article/f92f24fd02a34f38a77a83db4bd98880

The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry

Autor: Femke V. M. Mulder, Evelien F. H. I. Peeters, Jan Westerink, Fried J. T. Zwartkruis, Wendela L. de Ranitz-Greven

Publikováno v: Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-8 (2022)

Abstract Background MTOR inhibition is an effective treatment for many manifestations of tuberous sclerosis complex. Because mTOR inhibition is a disease modifying therapy, lifelong use will most likely be necessary. This study addresses the long-ter

Externí odkaz: https://doaj.org/article/c90b1abef9fe4f0994da3c5b1a92569a

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

Autor: Lisanne C. A. Smidt, Frank L. J. Visseren, Wendela L. de Ranitz-Greven, Hendrik M. Nathoe, L. Jaap Kappelle, Gert J. de Borst, Harold W. de Valk, Jan Westerink, the UCC-SMART Study Group

Publikováno v: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-10 (2021)

Abstract Background Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome trials (CVOTs). Applicabi

Externí odkaz: https://doaj.org/article/f3a9a7dde06648ed9979c46353fab63c

Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex

Autor: Mei Sheng Duh, Bruno Emond, Menno Vergeer, Wendela L. de Ranitz-Greven, Maureen P. Neary, Raluca Ionescu-Ittu, Floor E. Jansen, Bernard A. Zonnenberg

Publikováno v: Epilepsia Open, Vol 4, Iss 4, Pp 581-592 (2019)
Epilepsia Open

Objective To estimate health‐related quality of life (HRQoL) in patients with tuberous sclerosis complex (TSC) and associated manifestations and to identify potential factors associated with HRQoL in this population of patients. Methods We performe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5652411c533195bdc83e8842c7f120a7
https://doaj.org/article/14fdadbaa9134783972133ae0b26ebf0

Advanced Glycation End Products, Measured as Skin Autofluorescence, at Diagnosis in Gestational Diabetes Mellitus Compared with Normal Pregnancy

Autor: Harold W. de Valk, Wendela L. de Ranitz-Greven, Dieuwke C. Bos, Douwe H. Biesma, Joline W. J. Beulens, Gerard H. A. Visser, Wendy K. Poucki

Publikováno v: De Ranitz-Greven, W L, Bos, D C, Poucki, W K, Visser, G H A, Beulens, J W J, Biesma, D H & De Valk, H W 2012, ' Advanced glycation end products, measured as skin autofluorescence, at diagnosis in gestational diabetes mellitus compared with normal pregnancy ', Diabetes Technology and Therapeutics, vol. 14, no. 1, pp. 43-49 . https://doi.org/10.1089/dia.2011.0105
Diabetes Technology and Therapeutics, 14(1), 43-49. Mary Ann Liebert Inc.

Background: Advanced glycation end products (AGEs) are tissue proteins that accumulate with age and in diabetes mellitus (DM). AGEs can be measured by the AGE-Reader (DiagnOptics Technologies BV, Groningen, The Netherlands), which measures skin autof

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3e40dc2712e16adaa65cea549d3b0bd
https://doi.org/10.1089/dia.2011.0105